- UroToday Home
- Transformative Evidence
Transformative Evidence
The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos
Publications
Articles and Abstracts
FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting. Read More
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
BACKGROUND
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. Read More
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. Read More
Conference Coverage
Conference Highlights Written by Physician-Scientist
ESMO 2023: Association of Health-Related Quality of Life with Efficacy Outcomes in the VISION Study of Patients with mCRPC
Presented by Michael Morris, MD
The 2023 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Michael Morris discussing the association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer (mCRPC). Read More
EAU 2022: Metastatic Prostate Cancer: Possible Synergies Between Radioligand and Systemic Treatment in M1 Prostate Cancer? Future Perspectives
Presented by Ken Herrmann, MD, MBA
The 2022 EAU annual meeting featured a joint session of the EAU, EANM, ESMO, and ESTRO societies examining modern diagnostic and therapeutic approaches in prostate cancer, including a presentation by Dr. Ken Herrmann discussing future perspectives for possible synergies between radioligand and systemic treatment in M1 prostate cancer. Dr. Herrmann notes that synergism of treatment is the holy grail, emphasizing that in the VISION trial 46.0% of patients Read More
ASCO 2022: Tolerability of [177Lu]Lu-PSMA-617 By Treatment Exposure in Patients With Metastatic Castration-Resistant Prostate Cancer: A VISION Study Subgroup Analysis
Presented by Scott T. Tagawa, MD
At the 2022 ASCO Annual Meeting, the poster session focused on Prostate, Testicular, and Penile cancers on Monday afternoon included a presentation from Dr. Scott T. Tagawa discussing the tolerability of theranostic treatment with 177Lu-PSMA among men with metastatic castration-resistant prostate cancer (mCRPC), stratified by their treatment exposure, in men treated within the VISION trial. Read More
ASCO 2022: Outcome of Patients With PSMA PET/CT Screen Failure by VISION Criteria and Treated With 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis
Presented by Masatoshi Hotta, MD, PhD
At the 2022 ASCO Annual Meeting, the poster session focused on Prostate, Testicular, and Penile cancers and included a presentation from Dr. Masatoshi Hotta discussing outcomes of theranostic treatment with 177Lu-PSMA, among patients who would be deemed ineligible for therapy according to criteria used for inclusion in the VISION trial. Read More
ASCO 2022: [177Lu]Lu-PSMA-617 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial
Presented by Nitin Vaishampayan, MD, BA
At the 2022 ASCO Annual Meeting, the oral abstract session focused on Prostate, Testicular, and Penile cancers on Sunday morning included a presentation from Dr. Nitin Vaishampayan discussing subgroup analyses of the VISION trial examining 177Lu-PSMA-617 in men with heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC). Read More
ASCO 2022: [68Ga]Ga-PSMA-11 PET Baseline Imaging as a Prognostic Tool for Clinical Outcomes to [177Lu]Lu-PSMA-617 in Patients With mCRPC: A VISION Substudy
Presented by Andrew J. Armstrong, MD, MSc
At the 2022 ASCO Annual Meeting, the oral abstract session focused on Prostate, Testicular, and Penile cancers on Sunday morning included a presentation from Dr. Andrew J. Armstrong discussing the prognostic value of baseline [68Ga]Ga-PSMA-11 PET imaging in men undergoing theranostic treatment with 177Lu-PSMA-617 for heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) in the VISION trial. Read More
APCCC 2022: Lutetium-PSMA Therapy
Presented by Matthew Smith, MD, PhD
In the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), Dr. Matthew Smith discussed the role of prostate specific membrane antigen (PSMA)-lutetium radionuclide therapy, including considerations regarding monotherapy, combination therapy, and patient selection. Read More
ASCO GU 2022: Community Oncologists’ Perceptions of and Barriers To Access for 177LU-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
Presented by Ajeet Gajra FACP, MD
Dr. Garja presented a poster focused on understanding how community-based medical oncologists plan to integrate 177Lu-PSMA-617 into patient management. How 177Lu-PSMA-617 approval will affect the treatment landscape of mCRPC depends on how community-based medical oncologists uptake this new treatment approach. Read More
ASCO GU 2022: Dosimetry of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer: Results From the VISION Trial Sub-Study
Presented by Ken Herrmann, MD, MBA
During the 2022 GU ASCO Cancer Symposium, Dr. Herrmann presented a poster assessing [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) dosimetry among patients treated on the phase 3 VISION trial (NCT03511664). Read More
SUO 2021: VISION Trial: Integrating PSMA-Targeted Therapy for Advanced Prostate Cancer
Presented by Michael J. Morris, MD
(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included an advanced prostate cancer session and a presentation by Dr. Michael Morris discussing the VISION trial and integration of PSMA-targeted therapy for advanced prostate cancer. Read More
ASTRO 2021: Current and Future Management Paradigms for Metastatic Castrate-Resistant Prostate Cancer
Presented by Ana Kiess, MD, PhD
The 2021 ASTRO Annual Meeting included a joint ASTRO/SNMMI session on prostate cancer molecular imaging and radiotheranostics and a presentation by Dr. Ana Kiess discussing the current and future management paradigms for metastatic castration-resistant prostate cancer (mCRPC). Read More
APCCC 2021: Contagious Enthusiasm in PSMA-Driven Therapeutics
Presented by Eleni Efstathiou, MD
The APCCC 2021 meeting session discussing PSMA in diagnostics and therapy included a presentation by Dr. Eleni Efstathiou discussing the contagious enthusiasm of PSMA-driven therapeutics.
Read More
APCCC 2021: Best Use of Lutetium-PSMA and Where To Put It in Sequencing Therapies Including Treatment Monitoring
Presented by Charles Ryan, MD
The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PSMA in diagnostics and therapy included a presentation by Dr. Charles Ryan discussing the best use of Lutetium-PSMA and where to place it when sequencing therapies, including treatment monitoring. Read More
ESMO 2021: Health-Related Quality of Life, Pain and Safety Outcomes in the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients with mCRPC
Presented by Karim Fizazi, MD, PhD
The ESMO 2021 annual meeting’s prostate cancer mini oral session included a presentation by Dr. Karim Fizazi discussing health-related quality of life, pain, and safety outcomes in the phase 3 VISION study. [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) delivers β-particle radiation to prostate-specific membrane antigen (PSMA) expressing cells and the surrounding microenvironment. Read More
EAU 2021: Treatment Options That Offer a Survival Benefit in mCRPC Discussion: The TheraP and VISION Trials
Presented by Silke Gillessen, MD
Silke Gillessen discussed the recently published TheraP1 and VISION2 trials. Dr. Gillessen notes that in the metastatic castration-resistant prostate cancer (mCRPC) setting, we now have several treatment options that offer a survival benefit, including abiraterone, cabazitaxel, docetaxel, enzalutamide, radium-223, sipuleucel-T, olaparib, and now 177Lu-PSMA-617. Read More
EAU 2021: PSMA In Diagnostics and Treatment
Presented by Karim Fizazi, MD, Ph.D
Dr. Karim Fizazi finished off the thematic session of Treatment Sequencing in Metastatic Prostate Cancer with a presentation on the role of PSMA in diagnostics and treatment of metastatic prostate cancer. Read More
EAU 2021: An Overview of Systemic Treatment Options for mCRPC
Presented by Gero Kramer, MD
(UroToday.com) Dr. Gero Kramer reviews the systemic treatment options for metastatic castration-resistant prostate cancer (mCRPC) and highlights some recent developments. Read More
EAU 2021: Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
Presented by Johann De Bono, MD, MSc, Ph.D., FRCP, FMedSci
The EAU 2021 Annual Meeting included a presentation by Johann De Bono discussing the VISION trial, a phase 3 study of 177Lu-PSMA-617 in patients with mCRPC. As PSMA is highly expressed in prostate cancer and mCRPC lesions, the combination of PSMA-617 with the beta-emitter lutetium allows for the targeted delivery of ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment. Read More
SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC
Presented by Michael Morris, MD
(UroToday.com) There has been a dramatic and rapid proliferation of systemic therapy options in advanced prostate cancer since the introduction of docetaxel for metastatic castration resistant prostate cancer (mCRPC) in 2004. These newer treatments have included a number of novel hormonal therapies (including abiraterone acetate and enzalutamide), Read More
ASCO 2021: VISION Study Results Discussion: Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Presented by Mary-Ellen Taplin, MD
(UroToday.com) Dr. Taplin began her discussion of the VISION trial by first reviewing the current therapeutic landscape of prostate cancer. While there are many life-prolonging options, unfortunately, the duration of response to these therapies in sequence is often short. The VISION trial was set up to evaluate the use of lutetium-PSMA in late-stage advanced prostate cancer Read More
ASCO 2021: VISION Study Results – Phase III Study of Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Presented by Michael J. Morris, MD
(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic castration-resistant prostate cancer. Read More
ASCO 2021: Applying the Results of the Phase III VISION Trial, Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer to Clinical Practice - Discussion
Presented by Mary-Ellen Taplin, MD
Following Micheal Morris’s presentation of the results of the phase III VISION trial of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the Plenary Session of the 2021 ASCO, Dr. Mary-Ellen Taplin from the Dana Farber Cancer Institute provided a discussant overview of these data and helped to contextualize how we may apply them to our practices. Read More
ASCO 2021: Phase III Study of Lutetium-177-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
Presented by Micheal Morris, MD
In a plenary presentation at the 2021 ASCO Annual Meeting, Dr. Morris presented the first results of the VISION trial, a phase III study assessing lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Read More